Photocure ASA Reports Q1 2026 Results

Photocure ASA has reported its first-quarter results for 2026, showing Hexvix®/Cysview® revenues of NOK 139.0 million, marking a growth from NOK 125.3 million in Q1 2025. The company expects product revenue growth between 7% and 11% in 2026, alongside an adjusted EBITDA margin expansion. Key highlights include the installation of 11 new Saphira towers in the U.S., an increase of 21% in active accounts, and total revenue of NOK 264.6 million for the quarter. Significant regulatory updates include FDA’s reclassification pathway for BLC equipment and milestones regarding Cevira’s approval in China and EMA acceptance in Europe.